Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. - Wikidata - wikimedia - TriplyDB

Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.

Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.

http://www.wikidata.org/entity/Q39805065

about

MicroRNAs in mouse models of lymphoid malignancies MicroRNA, nutrition, and cancer prevention MicroRNAs in B-cell lymphomas: how a complex biology gets more complex A multi-targeted approach to suppress tumor-promoting inflammation miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.miRNA signature associated with outcome of gastric cancer patients following chemotherapy.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Epigenetics: A New Bridge between Nutrition and Health.Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy.MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4.Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.Diet, microRNAs and prostate cancer.Roles of small RNAs in tumor formation.Epigenetic mechanisms elicited by nutrition in early life.MicroRNAs and induced pluripotent stem cells for human disease mouse modeling.Epigenetics: a new link between nutrition and cancer.Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.Noncoding RNAs: New Players in Cancers.Noncoding RNAs in Therapeutic Resistance of Cancer.Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.miR-15a/16-1 enhances retinoic acid-mediated differentiation of leukemic cells and is up-regulated by retinoic acid.Modulation of microRNAs by phytochemicals in cancer: underlying mechanisms and translational significance.Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia * Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia.

P2860

Q24618980-FFC430BF-7166-40B1-8C0F-F92FA2034643 Q27010206-8808AB52-2DE1-4963-8832-781152C241D3 Q28254647-1F23A4E3-FEA0-4CCF-A79F-E5A6E49957C7 Q28393278-758DCFA7-57DE-4115-BDB3-F86FB3A1DEC7 Q33530333-AA790CF9-D94C-4730-88AF-0999673F098A Q33691885-7D0802DE-F049-4C46-A24C-9F72BF3ABDA2 Q34082270-11A13725-82C6-40C0-8F06-8AB255A793FB Q34195072-7791ED83-0398-4985-AE11-A462CD328EC6 Q34591910-DDE9E7CA-1D81-4C70-B64C-25F17DB289BF Q34769735-0E5DEFEF-29C9-4755-A8B2-C64B0BC3002B Q35039281-DAC1EE56-6289-4406-B881-21E118C6CB59 Q36422143-7BFC6DBE-0B1B-4688-B47C-22D381B794E5 Q36602853-F641296E-D73E-4EBA-8CE8-55B5D4CD709D Q37168329-363935C9-F641-4E0F-AF15-0D2566E899D5 Q37398927-60EC3782-C7D8-4FB4-8589-F2BB5F50835D Q37707217-B8442D5B-C765-43E4-93BD-9AD6DFC61F83 Q37759650-5FED1257-B7EC-4E0E-AB82-422F529CF7D3 Q37946981-8126D929-0213-494A-95D0-A571EC093619 Q38012445-B73AE42A-6342-4E5C-B49F-4CC7CB5E8E2E Q38126096-354761EE-6D71-48BD-B43F-253138E5C259 Q38346521-FECD6A16-0CE4-480E-AA30-51BC6C187614 Q38752301-1B5122A1-C943-4873-B919-A26D84DF41E7 Q38885461-A193DB41-9C53-4A14-B5B0-7B088972C14F Q38885495-166EEADB-3728-4673-905C-C799FB217306 Q39101593-AB45C91A-F7E9-49FE-8966-13BD277CAD83 Q39491088-ED650607-E9A7-4F53-A390-DC1FD366BE98 Q42180647-DF6D47F3-E8DC-4690-9862-09AD7AE69A76 Q42394984-464A91D1-15EE-4A02-8B72-66B956F7830A Q47933631-A04FA09F-E7CB-42D2-A062-656F733D3C5F

P2860

Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.

http://www.wikidata.org/entity/Q39805065

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Correcting miR-15a/16 genetic ...... CLL enhances drug sensitivity.

@en

Correcting miR-15a/16 genetic ...... CLL enhances drug sensitivity.

@nl

type

label

Correcting miR-15a/16 genetic ...... CLL enhances drug sensitivity.

@en

Correcting miR-15a/16 genetic ...... CLL enhances drug sensitivity.

@nl

prefLabel

Correcting miR-15a/16 genetic ...... CLL enhances drug sensitivity.

@en

Correcting miR-15a/16 genetic ...... CLL enhances drug sensitivity.

@nl

P1433

Q39805065-09DDB4C1-78AB-4335-8524-0C4129B2FDAD

P1476

Q39805065-F07903EC-FAB3-4F35-BB21-F8C99E309EC9

P2093

Q39805065-11A876BD-A73C-41C5-BC34-813E21C86199

Q39805065-161B2C6A-F4D6-473D-A777-A0D4FEDF2595

Q39805065-52E28642-29B6-48E6-AD3F-BF076E345E5E

Q39805065-544396B7-ADDC-4DBE-948B-8B5D4E500EDB

Q39805065-644F8DD6-6AFD-4065-827D-1DB19B179A1E

Q39805065-65950663-B58A-45E1-A92F-2EAC8647B95E

Q39805065-7EA243D8-93F4-4DD4-9F0F-CAAEB0D36705

Q39805065-FCB0F364-DE46-4971-9548-F466D73A3330

P304

Q39805065-E4EDD7AB-070B-4B5D-BF59-20C33CD42477

P31

Q39805065-E1C1B3C8-B012-4228-8477-37B844DB4460

P356

Q39805065-CA2EF15A-EE80-4B99-8CAC-256FD26B4D49

P433

Q39805065-D6E6AD0E-D9BA-47BA-A328-F1E60FBE5321

P478

Q39805065-74C01FB9-B0DE-4FFC-9948-B737721DAA00

P577

Q39805065-299BBFB8-1416-4BFF-8709-4EFAEC311D72

P5875

Q39805065-25ADC51A-1885-4DE1-A5F8-8167DC6BB6ED

P698

Q39805065-A40B4313-1989-4383-B674-0F00B0D7D9A8

P921

Q39805065-3EC37137-1E80-4042-B96D-FBED2050E390

P356

1535-7163.MCT-09-0127

P1433

Molecular Cancer Therapeutics

P1476

Correcting miR-15a/16 genetic ...... CLL enhances drug sensitivity.

@en

P2093

Alessia Baccarini

http://www.w3.org/2001/XMLSchema#string

Brian D Brown

http://www.w3.org/2001/XMLSchema#string

Brian J Scaglione

http://www.w3.org/2001/XMLSchema#string

Elizabeth S Raveche

http://www.w3.org/2001/XMLSchema#string

Erica Salerno

http://www.w3.org/2001/XMLSchema#string

Frederick D Coffman

http://www.w3.org/2001/XMLSchema#string

Gerald Marti

http://www.w3.org/2001/XMLSchema#string

Helen Fernandes

http://www.w3.org/2001/XMLSchema#string

P304

2684-2692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0127

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26783307

http://www.w3.org/2001/XMLSchema#string

P698

19723889

http://www.w3.org/2001/XMLSchema#string

P921